[{"address1": "100 Park Avenue", "address2": "23rd Floor", "city": "New York", "state": "NY", "zip": "10017", "country": "United States", "phone": "646 677 3870", "website": "https://www.actiniumpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sandesh C. Seth M.B.A., M.S.", "age": 59, "title": "Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1205000, "exercisedValue": 0, "unexercisedValue": 33756}, {"maxAge": 1, "name": "Mr. Steven  O'Loughlin BS", "age": 37, "title": "CFO & Corporate Secretary", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 590000, "exercisedValue": 0, "unexercisedValue": 10463}, {"maxAge": 1, "name": "Dr. Paul  Diamond Esq., Ph.D.", "title": "Vice President of Patent & Legal Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Avinash  Desai M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny  Hsieh", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sunitha  Lakshminarayanan", "title": "Senior VP, Head of CMC & Product Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Yarbrough", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lynn M. Bodarky M.B.A.", "age": 57, "title": "Chief Business Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. J. C. Simeon", "title": "Executive Director of Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhuri  Vusirikala M.D.", "title": "Vice President of Clinical Development BMT & Cellular Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.8, "open": 1.8, "dayLow": 1.7, "dayHigh": 1.85, "regularMarketPreviousClose": 1.8, "regularMarketOpen": 1.8, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 1.85, "beta": 0.147, "forwardPE": -2.3888888, "volume": 608333, "regularMarketVolume": 608333, "averageVolume": 811032, "averageVolume10days": 438220, "averageDailyVolume10Day": 438220, "bid": 1.71, "ask": 1.85, "bidSize": 1400, "askSize": 800, "marketCap": 53585568, "fiftyTwoWeekLow": 1.33, "fiftyTwoWeekHigh": 10.24, "priceToSalesTrailing12Months": 661.55023, "fiftyDayAverage": 4.985, "twoHundredDayAverage": 6.3819, "currency": "USD", "enterpriseValue": -28110124, "floatShares": 30368663, "sharesOutstanding": 31154400, "sharesShort": 2134139, "sharesShortPriorMonth": 2145250, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0685, "heldPercentInsiders": 0.020399999, "heldPercentInstitutions": 0.27403998, "shortRatio": 1.38, "shortPercentOfFloat": 0.0685, "impliedSharesOutstanding": 31154400, "bookValue": 1.435, "priceToBook": 1.1986064, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -42623000, "trailingEps": -1.51, "forwardEps": -0.72, "lastSplitFactor": "1:30", "lastSplitDate": 1597104000, "enterpriseToRevenue": -347.039, "enterpriseToEbitda": 0.605, "52WeekChange": -0.7204969, "SandP52WeekChange": 0.24014747, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "ATNM", "underlyingSymbol": "ATNM", "shortName": "Actinium Pharmaceuticals, Inc. ", "longName": "Actinium Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1356618600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "45c3a99a-9523-3f0f-ae76-8cfe4623774f", "messageBoardId": "finmb_7845787", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.72, "targetHighPrice": 9.8, "targetLowPrice": 2.0, "targetMeanPrice": 5.8, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 86037000, "totalCashPerShare": 2.762, "ebitda": -46485000, "totalDebt": 1849000, "quickRatio": 8.844, "currentRatio": 8.95, "totalRevenue": 81000, "debtToEquity": 4.218, "revenuePerShare": 0.003, "returnOnAssets": -0.30907, "returnOnEquity": -0.87961996, "freeCashflow": -20060124, "operatingCashflow": -33961000, "grossMargins": 1.0, "operatingMargins": -576.65436, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]